Premium
Effect of nucleoside analog use in patients with hepatitis B virus‐related hepatocellular carcinoma
Author(s) -
Nishikawa Hiroki,
Nishijima Norihiro,
Arimoto Akira,
Inuzuka Tadashi,
Kita Ryuichi,
Kimura Toru,
Osaki Yukio
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12169
Subject(s) - hepatocellular carcinoma , medicine , gastroenterology , hepatitis b virus , hepatitis b , nucleoside analogue , group a , group b , antiviral therapy , nucleoside , virus , immunology , chronic hepatitis , stereochemistry , chemistry
Aim To examine the effect of nucleoside analog ( NA ) therapy on clinical outcome in patients with hepatitis B virus ( HBV )‐related hepatocellular carcinoma ( HCC ) who underwent curative therapy. Methods A total of 131 patients with HBV ‐related HCC who underwent curative therapy were analyzed. They were divided into an NA group who received NA therapy ( n = 99, group A) and a control group ( n = 32, group B). Group A was further classified into two groups of patients who either received NA therapy before HCC therapy ( n = 34, group Aa) or who received NA therapy with initial HCC therapy ( n = 65, group Ab). Overall survival ( OS ) and recurrence‐free survival ( RFS ) were compared in the three groups. Results The 1‐ and 3‐year cumulative OS rates were both in group Aa, 100% and 88.0% in group Ab, and 100% and 75.7% in group B (overall significance, P = 0.002), respectively. The corresponding RFS rates were 93.1% and 36.0% in group Aa, 78.3% and 45.7% in group Ab, and 78.0% and 38.0% in group B (overall significance, P = 0.734), respectively. Multivariate analysis revealed that being part of group Aa ( P < 0.001) or group Ab ( P < 0.001) and having albumin levels of 4.0 g/dL or more ( P = 0.040) were significantly associated with OS , while HCC stage ( P = 0.001) and hepatitis B e‐antigen positivity ( P < 0.001) were independent predictors linked to RFS . Conclusion NA therapy in patients with HBV ‐related HCC may improve survival after curative therapy.